Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
1.44
USD
|
-2.70%
|
|
-11.66%
|
-11.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
92.2
|
116.3
|
185
|
128
|
86.96
|
78.12
|
-
|
-
|
Enterprise Value (EV)
1 |
-22.43
|
35.68
|
74.37
|
44.07
|
86.96
|
26.57
|
70.82
|
78.12
|
P/E ratio
|
-1.72
x
|
-3.27
x
|
-3.81
x
|
-4.32
x
|
-1.89
x
|
-1.79
x
|
-1.55
x
|
-1.97
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
1,378
x
|
192
x
|
57
x
|
171
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
1,378
x
|
65.3
x
|
51.7
x
|
171
x
|
EV / EBITDA
|
399,872
x
|
-1,073,762
x
|
-1,583,529
x
|
-1,392,696
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
0.51
x
|
-0.97
x
|
-1.86
x
|
-1.3
x
|
-
|
-0.42
x
|
-0.96
x
|
-4.57
x
|
FCF Yield
|
195%
|
-103%
|
-53.8%
|
-76.9%
|
-
|
-238%
|
-104%
|
-21.9%
|
Price to Book
|
0.86
x
|
1.49
x
|
1.76
x
|
1.45
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,105
|
28,228
|
44,186
|
44,204
|
58,883
|
58,883
|
-
|
-
|
Reference price
2 |
3.532
|
4.118
|
4.187
|
2.897
|
1.477
|
1.327
|
1.327
|
1.327
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.0631
|
0.407
|
1.371
|
0.457
|
EBITDA
|
-56.11
|
-33.23
|
-46.97
|
-31.64
|
-
|
-
|
-
|
-
|
EBIT
1 |
-56.77
|
-33.94
|
-47.63
|
-32.24
|
-44.91
|
-52.08
|
-68.65
|
-56.95
|
Operating Margin
|
-
|
-
|
-
|
-
|
-71,181.01%
|
-12,795.66%
|
-5,007.54%
|
-12,460.98%
|
Earnings before Tax (EBT)
1 |
-53.25
|
-33.98
|
-45.63
|
-29.48
|
-42.67
|
-46.31
|
-65.2
|
-54.38
|
Net income
1 |
-53.25
|
-33.98
|
-45.63
|
-29.48
|
-42.67
|
-46.38
|
-61.66
|
-54.38
|
Net margin
|
-
|
-
|
-
|
-
|
-67,629.62%
|
-11,394.96%
|
-4,497.79%
|
-11,899.78%
|
EPS
2 |
-2.050
|
-1.260
|
-1.100
|
-0.6700
|
-0.7800
|
-0.7400
|
-0.8575
|
-0.6733
|
Free Cash Flow
1 |
-43.8
|
-36.62
|
-39.97
|
-33.91
|
-
|
-63.31
|
-73.53
|
-17.09
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-15,555.04%
|
-5,362.95%
|
-3,739.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0608
|
0.00229
|
0.036
|
0.0893
|
0.091
|
0.203
|
-
|
-
|
EBITDA
|
-12.83
|
-14.71
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13
|
-14.86
|
-1.087
|
-8.594
|
-7.699
|
-10.59
|
-9.856
|
-11.15
|
-13.31
|
-12.49
|
-12.63
|
-13.01
|
-13.98
|
-18.33
|
-20.05
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18,340.21%
|
-581,058.52%
|
-34,652.3%
|
-14,135.98%
|
-14,298.54%
|
-6,886.54%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.67
|
-14
|
0.4654
|
-7.922
|
-8.026
|
-11.08
|
-8.202
|
-7.451
|
-15.93
|
-9.657
|
-11.55
|
-12.04
|
-13.11
|
-17.58
|
-19.35
|
Net income
1 |
-12.67
|
-14
|
0.4654
|
-7.922
|
-8.026
|
-11.08
|
-8.202
|
-7.451
|
-15.93
|
-9.657
|
-11.73
|
-12.11
|
-12.91
|
-17.58
|
-19.35
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,255.61%
|
-695,640.17%
|
-26,795.89%
|
-13,135.28%
|
-13,304.12%
|
-6,360.84%
|
-
|
-
|
EPS
2 |
-0.2900
|
-0.3200
|
0.0100
|
-0.1800
|
-0.1800
|
-0.2500
|
-0.1400
|
-0.1300
|
-0.2800
|
-0.1700
|
-0.1975
|
-0.1900
|
-0.1925
|
-0.2500
|
-0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/12/22
|
8/5/22
|
11/9/22
|
3/22/23
|
5/11/23
|
8/10/23
|
11/1/23
|
3/21/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
115
|
80.6
|
111
|
84
|
-
|
51.6
|
7.3
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.8
|
-36.6
|
-40
|
-33.9
|
-
|
-63.3
|
-73.5
|
-17.1
|
ROE (net income / shareholders' equity)
|
-41.2%
|
-36.7%
|
-49.8%
|
-30.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-37.9%
|
-32.4%
|
-42.8%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
140.4
|
104.9
|
106.7
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.120
|
2.760
|
2.380
|
2.000
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.350
|
-0.9600
|
-0.7600
|
-
|
-
|
-
|
-
|
Capex
1 |
0.59
|
0.09
|
0.04
|
0.16
|
-
|
0.06
|
0.11
|
0.13
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
14.13%
|
7.88%
|
28.45%
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
1.327
EUR Average target price
8.375
EUR Spread / Average Target +531.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.66% | 84.79M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|